Shenzhen Weiguang Biological Products Co Ltd
002880
Company Profile
Business description
Shenzhen Weiguang Biological Products Co Ltd is the pharmaceutical company. It is mainly engaged in the research and development, production and sales of blood products. The company's products portfolio includes human albumin, intravenous immunoglobulin (pH4), lyophilized human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, tetanus Human immunoglobulin, histamine human immunoglobulin, human fibrinogen, a total of 21 varieties of 21 specifications.
Contact
Guangming Street
No. 3402, Guangqiao Avenue
Guangming New District
Guangdong Province
Guangming518107
CHNT: +86 75527402880
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
846
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
stocks
Insights from reporting season: So far, so good
We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,570.90 | 30.80 | -0.36% |
| CAC 40 | 8,154.51 | 31.93 | 0.39% |
| DAX 40 | 22,287.56 | 27.09 | -0.12% |
| Dow JONES (US) | 43,368.61 | 808.04 | -1.83% |
| FTSE 100 | 8,659.37 | 3.60 | -0.04% |
| HKSE | 23,477.92 | 900.94 | 3.99% |
| NASDAQ | 19,528.71 | 433.65 | -2.17% |
| Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
| NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
| S&P 500 | 6,012.11 | 105.41 | -1.72% |
| S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
| SSE Composite Index | 3,379.11 | 28.33 | 0.85% |